Analyst Insights - Digital Health Posts

Read our Analysts’ insights and expert opinions on the latest healthcare technology industry developments and market trends. Signify Research provides both free insights and premium insights which are only available to subscribers of "Signify Premium Insights". Click on the premium insights link below to filter for just the premium content.



AI in Drug Development & Clinical Trials Market to Reach $3.0 Billion by 2024

25th February 2021 – The world market for AI used in drug development and clinical trials is set to reach almost $3.0 billion by 2024. This is according to a new report from Signify Research, an independent supplier of market intelligence and consultancy to the global healthcare technology industry.

Signify Premium Insight: Intelerad Acquires LumedX – Now the Work Begins

Signify Premium Insights Subscription Required

February 25th 2021 – News broke last week that imaging IT vendor Intelerad has acquired LumedX, the latest in a rapid-fire acquisition streak from the imaging IT vendor, In this Insight we analyse the implications of the acquisition for the firms and postulate to the drivers and market context that have led to the deal.

Signify Premium Insight: Vendor Financials Roundup – The Health of the Sector

Signify Premium Insights Subscription Required

February 23rd 2021 – The Covid pandemic made 2020 a year of unprecedented volatility for vendors. These tumultuous conditions are captured in their financial reports, which also reveal the key trends that impacted the medical imaging and imaging IT sectors across the year.

Signify Premium Insight: Fuji Launches Screening Centre in India

Signify Premium Insights Subscription Required

18th February 2021 – Fujifilm has revealed it is opening a medical screening centre in India. This insight assesses the motivations for the move, as well as looking at the potential impacts.

Are EMR-based Oncology Modules Threatening Best-of-Breed Oncology IT?

18th February 2021 – With several EMR vendors now marketing their own Oncology-specific modules, healthcare providers will be deciding between best-of-breed and EMR-based offerings; so how this will affect the existing Oncology Information System (OIS) market, and how will incumbent vendors respond to the challenge?